Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.73 |
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.55 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pincainide SCHEMBL2110148 | 1.00 | MEN1 (0.73) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL22407740 | 1.00 | MEN1 (0.73) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| Pyrrocaine SCHEMBL25718 | 0.98 | MEN1 (0.70) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| Pyrrocaine SCHEMBL10757216 | 0.97 | MEN1 (0.68) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| Pyrrocaine SCHEMBL1651381 | 0.95 | MEN1 (0.67) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL2327539 | 0.92 | ALDH1A1 (0.64) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL22407703 | 0.90 | MEN1 (0.60) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL6258331 | 0.87 | ALOX15 (0.67) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL22407733 | 0.87 | ALDH1A1 (0.67) | MEN1KMT2APOLBTDP1ALDH1A1 | |
| SCHEMBL30391696 | 0.87 | ALDH1A1 (0.67) | MEN1KMT2APOLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | claimed |
| EP-3938345-B1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2025-08-21 | — | — | US | disclosed |
| CN-119874561-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-113950471-B | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11603355-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-03-14 | — | — | US | disclosed |
| EP-3938345-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| CN-113950471-A | Charged ion channel blockers and methods of use thereof | 诺西恩医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-10780083-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-20200289490-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185830-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-8163803-B2 | less anesthetic activity, but with more anti-inflammatory and spasmolytic activity; asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance | Fundação Oswaldo Cruz—FIOCRUZ (BR) | 2012-04-24 | — | — | US | disclosed |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | FUNDÇÃO OSWALDO CRUZ-FIOCRUZ (BR) | 2008-09-11 | — | — | US | disclosed |
| WO-2005025498-A2 | SUBSTITUTED ACETANILIDES AND BENZAMIDES FOR THE TREATMENT OF ASTHMA AND PULMONARY INFLAMMATION | CORUS PHARMA (US) | 2005-03-24 | — | — | WO | disclosed |
| US-4499100-A | CARDIOUVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885POLB 1996/4885 |
| US-20200289490-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | MEN1 3101/4885KMT2A 2434/4885POLB 1989/4885 |
| US-20250263375-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885POLB 1996/4885 |
| US-10780083-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | MEN1 3101/4885KMT2A 2434/4885POLB 1989/4885 |
| US-11603355-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885POLB 1996/4885 |
| US-20230192613-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885POLB 1996/4885 |
| US-20080221206-A1 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease | LTA, LCT, LTC4S | MEN1 3694/4885KMT2A 3557/4885POLB 2684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.